Literature DB >> 2989700

Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells.

D S Anson, D E Austen, G G Brownlee.   

Abstract

Haemophilia B, or Christmas disease, is an inherited X-chromosome-linked bleeding disorder caused by a defect in clotting factor IX and occurs in about 1 in 30,000 males in the United Kingdom. Injection of factor IX concentrate obtained from blood donors allows most patients to be successfully managed. However, because of impurities in the factor IX concentrate presently in use, this treatment involves some risk of infection by blood-borne viruses such as non-A, non-B hepatitis and the virus causing acquired immune deficiency syndrome (AIDS). Because of the recent concern about the increasing incidence of AIDS amongst haemophiliacs, a factor IX preparation derived from a source other than blood is desirable. Here, we report that after introduction of human factor IX DNA clones into a rat hepatoma cell line using recombinant DNA methods, we were able to isolate small amounts of biologically active human factor IX.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989700     DOI: 10.1038/315683a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  17 in total

Review 1.  The mammary gland as a bioreactor: expression, processing, and production of recombinant proteins.

Authors:  A J Clark
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-07       Impact factor: 2.673

Review 2.  Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase.

Authors:  C Vermeer
Journal:  Biochem J       Date:  1990-03-15       Impact factor: 3.857

3.  Expression of active human blood clotting factor IX in transgenic mice: use of a cDNA with complete mRNA sequence.

Authors:  K H Choo; K Raphael; W McAdam; M G Peterson
Journal:  Nucleic Acids Res       Date:  1987-02-11       Impact factor: 16.971

4.  Purification and identification of bovine liver gamma-carboxylase.

Authors:  K L Berkner; M Harbeck; S Lingenfelter; C Bailey; C M Sanders-Hinck; J W Suttie
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

5.  Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B.

Authors:  D Armentano; A R Thompson; G Darlington; S L Woo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

6.  Mammalian cell survival and processing in supercritical CO(2).

Authors:  Patrick J Ginty; Daniel Howard; Felicity R A J Rose; Martin J Whitaker; John J A Barry; Patrick Tighe; Stacey R Mutch; Gulay Serhatkulu; Richard O C Oreffo; Steven M Howdle; Kevin M Shakesheff
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

7.  Fixing human factor IX (fIX): correction of a cryptic RNA splice enables the production of biologically active fIX in the mammary gland of transgenic mice.

Authors:  F Yull; G Harold; R Wallace; A Cowper; J Percy; I Cottingham; A J Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  Targeting expression to the mammary gland: intronic sequences can enhance the efficiency of gene expression in transgenic mice.

Authors:  C B Whitelaw; A L Archibald; S Harris; M McClenaghan; J P Simons; A J Clark
Journal:  Transgenic Res       Date:  1991-12       Impact factor: 2.788

9.  The propeptide region of clotting factor IX is a signal for a vitamin K dependent carboxylase: evidence from protein engineering of amino acid -4.

Authors:  P Galeffi; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1987-11-25       Impact factor: 16.971

Review 10.  Production of pharmaceutical proteins in milk.

Authors:  I Wilmut; A L Archibald; M McClenaghan; J P Simons; C B Whitelaw; A J Clark
Journal:  Experientia       Date:  1991-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.